AstraZeneca sells rights to anaesthetics products to Aspen for $520 million upfront
June 9, 2016Research and Development, Sales and Marketing AstraZeneca, Licencing, anaesthetics, aspen, marketing agreement
UK drug firm AstraZeneca (LSE: AZN) on Thursday said it has agreed to sell rights for its anaesthetics portfolio to Aspen …
Clarissa Lewis joins the Clinical Trials Team at Woodley Equipment Company
June 8, 2016Medical Equipment Supplier, medical equip rental, woodley equipment
We are pleased to welcome Clarissa Lewis to Woodley Equipment Company Clinical Trials Division as Accounts Supervisor based at our …
New data on biosimilars of the big three anti-TNF drugs presented at EULAR 2016
June 8, 2016Research and Development, Sales and Marketing Benepali, Biogen, Enbrel, Flixabi, Humira, Remicade, Samsung Bioepis, biosimilars, eular 2016, sb5
Samsung Bioepis has presented data at EULAR 2016 on three biosimilars of the highly selling anti-TNF drugs Remicade (infliximab), Enbrel …
India-based Cipla gets new chief financial officer
June 8, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cipla, Dr Reddy's, cfo, dr reddys
Cipla (NSE: CIPLA) has poached a top executive from Dr. Reddy’s by naming Kedar Upadhye as its new global chief …
Novartis to compare Cosentyx with Humira in new clinical trials
June 8, 2016Research and Development Cosentyx, Humira, Novartis, comparison, eular 2016
Novartis has announced that it plans to directly compare Cosentyx (secukinumab) versus Humira (adalimumab) in patients with ankylosing spondylitis and …
Biogen MS drug misses primary endpoint in Phase II trial
June 8, 2016Research and Development Biogen, MS, multiple sclerosis, opicinumab
Biogen has reported top-line results in the Phase II trial evaluating opicinumab (anti-Lingo-1) in relapsing forms of multiple sclerosis, with …
Losses and profit forecast cuts send shares tumbling again at Valeant
June 8, 2016Research and Development, Sales and Marketing Shares, Valeant, cut, forecast, tumbling
Valeant Pharmaceuticals has published its results for the first quarter, which has seen the firm post a net loss of …
Roche says combination therapy with its Avastin and Tarceva gets European backing for lung cancer treatment
June 8, 2016Research and Development, Sales and Marketing European Commission, NSCL, RegulationC, Roche, Tarceva, avastin, drug trial, lung cancer
Cancer drugmaker Roche (SIX: ROG) on Wednesday said the European Commission has approved its Avastin (bevacizumab) in combination with Tarceva …
MSD says Phase III trials for Keytruda to treat advanced melanoma shows better survival
June 8, 2016Research and Development ASCO, MSD, Merck & Co, PD-L1, advanced melanoma, drug trial, immuno-oncology, keytruda
Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced melanoma showed over half …
MSD to collaborate with Fujifilm Diosynth on new microbial biologics facility
June 7, 2016Manufacturing and Production, Research and Development MSD, Merck, fujifilm diosynth
MSD, known as Merck in the US and Canada, has entered into a collaboration with Fujifilm Diosynth Biotechnologies to invest …
Drug Pricing: Cancer drugs cost the most in US, but most unaffordable in India, China – Study
June 7, 2016Medical Communications, Research and Development, Sales and Marketing ASCO, Drug pricing, oncology, social
Cancer drugs are less affordable in low-income countries, despite the lower retail prices, according to a study released at the …
The Pharmafocus ASCO round-up
June 7, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, Pharmafocus
As the curtain falls on another annual ASCO (American Society of Clinical Oncology) congress, catch up on all the biggest …
AstraZeneca says latest study data for Lynparza suggest improvement in overall survival in ovarian cancer
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AstraZeneca, NHS, lynparza, ovarian cancer, regulation
UK drugmaker AstraZeneca (LSE: AZN) said mid-stage trials for Lynparza (olaparib) maintenance therapy suggest an improvement in overall survival (OS) …
Judge reverses verdict in MSD/Gilead hepatitis C dispute
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Gilead, MSD, Merck, dispute, patent, reversal, sovaldi
A US district judge has reversed a previous court decision which favoured MSD, called Merck in the US, over Gilead …
FDA approves Allergan hypertension fixed-dose combo, Byvalson
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, FDA, US, angiotensin ii, approval, beta blocker, byvalson, hypertension, nebivolol, valsartan
Allergan has announced that the US Food and Drug Administration (FDA) has approved its fixed-dose combination, Byvalson (nebivolol and valsartan), …
Amgen showcases positive Phase III multiple myeloma drug at ASCO
June 7, 2016Manufacturing and Production, Research and Development ASCO, Amgen, Kyprolis, dexamethasone, lenalidomide, multiple myeloma
Amgen (NASDAQ: AMGN) has presented data showing a statistically significant increase in progression-free survival and overall response rate in multiple …
Grünenthal chief executive Eric-Paul Pâques to retire; new CEO named
June 7, 2016CEO, Grünenthal Group, appointment
Germany-based Grünenthal Group on Tuesday named Gabriel Baertschi its chief executive officer effective October 1, 2016. He succeeds Eric-Paul Pâques who will retire at the end of …
Novartis says Phase II data for rare lung cancer showed overall response rate of 63%
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, Novartis, Tafinlar, drug trial, lung cancer, mekinist
Swiss drugmaker Novartis (VTX: NOVN) said combination mid-stage trials for the drug to treat a rare and aggressive form of …
Pivotal avelumab data in Merkel cell carcinoma presented at ASCO
June 6, 2016Manufacturing and Production, Research and Development ASCO, Merck, Pfizer, avelumab, merkel cell carcinoma
New data presented at the American Society of Clinical Oncology’s annual general meeting has shown that avelumab, an investigational anti-PD-L1 …
AbbVie says Stemcentrx’ lung cancer drug shows some benefits in early trials
June 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t
US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
